OBJECTIVE: Familial Mediterranean fever (FMF) has traditionally been considered an autosomal-recessive disease; however, it has been observed that a substantial number of patients with clinical FMF possess only 1 demonstrable MEFV mutation. The purpose of this study was to perform an extensive search for a second MEFV mutation in 46 patients diagnosed clinically as having FMF and carrying only 1 high-penetrance FMF mutation. METHODS: MEFV and other candidate genes were sequenced by standard capillary electrophoresis. In 10 patients, the entire 15-kb MEFV genomic region was resequenced using hybridization-based chip technology. MEFV gene expression levels were determined by quantitative reverse transcription-polymerase chain reaction. Pyrin protein levels were examined by Western blotting. RESULTS: A second MEFV mutation was not identified in any of the patients who were screened. Haplotype analysis did not identify a common haplotype that might be associated with the transmission of a second FMF allele. Western blots did not demonstrate a significant difference in pyrin levels between patients with a single mutation and those with a double mutation; however, FMF patients of both types showed higher protein expression as compared with controls and with non-FMF patients with active inflammation. Screening of genes encoding pyrin-interacting proteins identified rare mutations in a small number of patients, suggesting the possibility of digenic inheritance. CONCLUSION: Our data underscore the existence of a significant subset of FMF patients who are carriers of only 1 MEFV mutation and demonstrate that complete MEFV sequencing is not likely to yield a second mutation. Screening for the set of the most common mutations and detection of a single mutation appears to be sufficient in the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicine.
OBJECTIVE:Familial Mediterranean fever (FMF) has traditionally been considered an autosomal-recessive disease; however, it has been observed that a substantial number of patients with clinical FMF possess only 1 demonstrable MEFV mutation. The purpose of this study was to perform an extensive search for a second MEFV mutation in 46 patients diagnosed clinically as having FMF and carrying only 1 high-penetrance FMF mutation. METHODS:MEFV and other candidate genes were sequenced by standard capillary electrophoresis. In 10 patients, the entire 15-kb MEFV genomic region was resequenced using hybridization-based chip technology. MEFV gene expression levels were determined by quantitative reverse transcription-polymerase chain reaction. Pyrin protein levels were examined by Western blotting. RESULTS: A second MEFV mutation was not identified in any of the patients who were screened. Haplotype analysis did not identify a common haplotype that might be associated with the transmission of a second FMF allele. Western blots did not demonstrate a significant difference in pyrin levels between patients with a single mutation and those with a double mutation; however, FMFpatients of both types showed higher protein expression as compared with controls and with non-FMFpatients with active inflammation. Screening of genes encoding pyrin-interacting proteins identified rare mutations in a small number of patients, suggesting the possibility of digenic inheritance. CONCLUSION: Our data underscore the existence of a significant subset of FMFpatients who are carriers of only 1 MEFV mutation and demonstrate that complete MEFV sequencing is not likely to yield a second mutation. Screening for the set of the most common mutations and detection of a single mutation appears to be sufficient in the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicine.
Authors: C Cazeneuve; T Sarkisian; C Pêcheux; M Dervichian; B Nédelec; P Reinert; A Ayvazyan; J C Kouyoumdjian; H Ajrapetyan; M Delpech; M Goossens; C Dodé; G Grateau; S Amselem Journal: Am J Hum Genet Date: 1999-07 Impact factor: 11.025
Authors: Arturo Diaz; Chunbo Hu; Daniel L Kastner; Philip Schaner; Anthony M Reginato; Neil Richards; Deborah L Gumucio Journal: Arthritis Rheum Date: 2004-11
Authors: J-W Yu; J Wu; Z Zhang; P Datta; I Ibrahimi; S Taniguchi; J Sagara; T Fernandes-Alnemri; E S Alnemri Journal: Cell Death Differ Date: 2006-02 Impact factor: 15.828
Authors: A Bernot; C da Silva; J L Petit; C Cruaud; C Caloustian; V Castet; M Ahmed-Arab; C Dross; M Dupont; D Cattan; N Smaoui; C Dodé; C Pêcheux; B Nédelec; J Medaxian; M Rozenbaum; I Rosner; M Delpech; G Grateau; J Demaille; J Weissenbach; I Touitou Journal: Hum Mol Genet Date: 1998-08 Impact factor: 6.150
Authors: H J Lachmann; B Sengül; T U Yavuzşen; D R Booth; S E Booth; A Bybee; J R Gallimore; M Soytürk; S Akar; M Tunca; P N Hawkins Journal: Rheumatology (Oxford) Date: 2006-01-10 Impact factor: 7.580
Authors: Cristian Vergara; Arturo Borzutzky; Miguel A Gutierrez; Sergio Iacobelli; Eduardo Talesnik; María E Martinez; Lilith Stange; Javier Basualdo; Viviana Maluje; Renato Jimenez; Roberto Wiener; Javier Tinoco; Elena Jarpa; Juan I Aróstegui; Jordi Yagüe; Manuel Alvarez-Lobos Journal: Clin Rheumatol Date: 2012-01-28 Impact factor: 2.980
Authors: Jae Jin Chae; Young-Hun Cho; Geun-Shik Lee; Jun Cheng; P Paul Liu; Lionel Feigenbaum; Stephen I Katz; Daniel L Kastner Journal: Immunity Date: 2011-05-19 Impact factor: 31.745
Authors: F S Ong; H Vakil; Y Xue; J Z Kuo; K H Shah; R B Lee; K E Bernstein; D L Rimoin; T Getzug; K Das; J L Deignan; J I Rotter; W W Grody Journal: Clin Genet Date: 2012-11-07 Impact factor: 4.438